- Email: [email protected]
Predictors for Survival After Radium-223 Treatment for Castration-Resistant Metastatic Prostate Cancer
Poster Viewing E255
Volume 96 Number 2S Supplement 2016 Abstract 2619; Table 1. Summary of Results
n 156
PreEBRT (Gy/fr)
HDR-BT (Gy/fr/ day)
39Gr/ 13fr
18Gy/ 2fr/ 1dy
Total BED (a/ ratio;1.5)
median F/ U(month)
ADT situation (%)
243
47
71.2
b
OS intermediate risk (%)
OS low risk (%)
b-NED high risk (%)
b-NED intermediate risk (%)
b-NED low risk (%)
G3GU toxicities (%)
G3GI toxicities (%)
100
100
96.5
100
100
7.1
0
OS high risk (%) 91.8
biochemical no evidence of disease(b-NED) rate was 96.5%, 100% and 100% for high, intermediate and low risk respectively analyzed by D’Amico risk grouping. Of all the dead or recurrence cases were in the high-risk group. The assessment of genitourinary (GU) and gastrointestinal (GI) toxicities was done using the Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Grade-3 late GU toxicity rate was 7.1%, and no Grade-3 late GI toxicity. Conclusion: The efficacy and safety of this treatment which the 2 fractions of HDR-BT were administered within a single day were satisfactory so far. However, longer-term follow-up is necessary. Author Disclosure: J. Liu: None. R. Sasamoto: None. M. Kaidu: None. F. Ayukawa: None. N. Yamana: None. K. Tanaka: None. G. Kawaguchi: None. A. Ohta: None. K. Maruyama: None. E. Abe: None. H. Saitou: None. T. Nakano: None. H. Aoyama: None.
2620 Predictors for Survival After Radium-223 Treatment for CastrationResistant Metastatic Prostate Cancer E. Anderson,1 W.W. Wong,1 H. Mohammadi,1 T.B. Daniels,1 S. Vora,1 S.E. Schild,2 S.R. Keole,1 C.R. Choo,3 K.S. Tzou,4 A. Bryce,1 T.H. Ho,1 and F.J. Quevedo3; 1Mayo Clinic Arizona, Phoenix, AZ, 2Mayo Clinic, Phoenix, AZ, 3Mayo Clinic Rochester, Rochester, MN, 4Mayo Clinic, Jacksonville, FL Purpose/Objective(s): Radium-223 (R223) has been shown to improve survival of patients with castration-resistant metastatic prostate cancer. The purpose of our study is to identify factors that predict the overall survival after R223 treatment (tmt). Materials/Methods: The medical records of 64 patients at our institution were reviewed. Data on patient and disease characteristics, and tmt response were collected. Kaplan-Meier estimate of survival time was calculated. Univariate analysis with log-rank method and multivariate
analysis with Cox Proportional Hazards Model were performed to evaluate factors associated with survival. Results: The results are presented in Table 1. Conclusion: In our study, several factors were associated with better survival on univariate analysis, including no prior chemotherapy, 5 bone metastases, baseline PSA36ng/ml, baseline ALP115U/L, baseline hemoglobin>12g/dl, ALP response, PSA decrease during treatment, and PSA increase less than 25% from baseline during treatment. In multivariate analysis, 5 bone metastasis, baseline ALP115U/L, and ALP response remained significant predictors of survival Author Disclosure: E. Anderson: None. W.W. Wong: None. H. Mohammadi: None. T.B. Daniels: None. S. Vora: None. S.E. Schild: None. S.R. Keole: Stock; ViewRay. C. Choo: None. K.S. Tzou: None. A. Bryce: Research Grant; Isis Pharmaceuticals, Bayer, Merck, Aragon, Novartis, BMS. T.H. Ho: None. F.J. Quevedo: None.
2621 Ten-Year Data Update: Is There Still a Role for Postoperative Radiation Therapy in High-Risk Stage III Renal Cell Carcinoma? A Retrospective Study L. Avile´s,1 M. Filomia,2 W.A. Baquero,1 L.E. Rafailovici,3 C.A. Cardiello,4 E. Fernandez,5 J. Chiozza,3 and C. Donoso6; 1Vidt Centro Medico, Buenos Aires, Argentina, 2Vidt Centro Medico - 21st. Century Oncology, Buenos Aires, Argentina, 3Vidt Centro Medico - 21st Century Oncology, Buenos Aires, Argentina, 4Hospital Militar Central, Buenos Aires 1428, Argentina, 521st Century Oncology, Fort Lauderdale, FL, 6Vidt Medical Center, Buenos Aires, Argentina Purpose/Objective(s): We updated our data with 10 year follow up to determine if there is still a role for adjuvant radiation therapy in patients of renal cell carcinoma (RCC) with adverse pathological prognostic factors, such as perirenal fat extension, capsule infiltration, positive nodes or
Abstract 2620; Table 1. Factor Baseline ECOG PS Prior chemotherapy Prior sipuleucel-T Concurrent use of zoledronate or denosumab with R223 tmt Extent of bone metastasis PSA before R223 tmt Alkaline phosphatase (ALP) before R223 tmt Hemoglobin before R223 tmt ALP response after R223 tmt PSA decrease during R223 tmt PSA increase>25% from baseline during R223 tmt
0,1 2,3 Yes No Yes No Yes No 5 lesions > 5 lesions 36ng/ml >36ng/ml 115U/L >115U/L 12g/dl >12g/dl Yes No Yes No Yes No
Median survival(mo)
12-mo survival
Univariate analysis (P value)
12.9 11.3 12.6 Not reached 16 12.8 12.8 12.9 Not reached 12.6 Not reached 11.5 Not reached 9.2 10 16 Not reached 12.5 Not reached 12.8 12.6 Not reached
67% 43% 53% 71% 76% 60% 63% 57% 100% 56% 77% 43% 87% 30% 40% 78% 80% 52% 91% 60% 56% 100%
0.62 0.028
Multivariate analysis (P value)
0.17
0.47 0.62 0.0023 <0.0001
0.0096 0.93
0.0004
0.0076
0.0026
0.75
0.015
0.02
0.0095
0.49
0.0061
0.24
Volume 96 Number 2S Supplement 2016 Abstract 2619; Table 1. Summary of Results
n 156
PreEBRT (Gy/fr)
HDR-BT (Gy/fr/ day)
39Gr/ 13fr
18Gy/ 2fr/ 1dy
Total BED (a/ ratio;1.5)
median F/ U(month)
ADT situation (%)
243
47
71.2
b
OS intermediate risk (%)
OS low risk (%)
b-NED high risk (%)
b-NED intermediate risk (%)
b-NED low risk (%)
G3GU toxicities (%)
G3GI toxicities (%)
100
100
96.5
100
100
7.1
0
OS high risk (%) 91.8
biochemical no evidence of disease(b-NED) rate was 96.5%, 100% and 100% for high, intermediate and low risk respectively analyzed by D’Amico risk grouping. Of all the dead or recurrence cases were in the high-risk group. The assessment of genitourinary (GU) and gastrointestinal (GI) toxicities was done using the Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Grade-3 late GU toxicity rate was 7.1%, and no Grade-3 late GI toxicity. Conclusion: The efficacy and safety of this treatment which the 2 fractions of HDR-BT were administered within a single day were satisfactory so far. However, longer-term follow-up is necessary. Author Disclosure: J. Liu: None. R. Sasamoto: None. M. Kaidu: None. F. Ayukawa: None. N. Yamana: None. K. Tanaka: None. G. Kawaguchi: None. A. Ohta: None. K. Maruyama: None. E. Abe: None. H. Saitou: None. T. Nakano: None. H. Aoyama: None.
2620 Predictors for Survival After Radium-223 Treatment for CastrationResistant Metastatic Prostate Cancer E. Anderson,1 W.W. Wong,1 H. Mohammadi,1 T.B. Daniels,1 S. Vora,1 S.E. Schild,2 S.R. Keole,1 C.R. Choo,3 K.S. Tzou,4 A. Bryce,1 T.H. Ho,1 and F.J. Quevedo3; 1Mayo Clinic Arizona, Phoenix, AZ, 2Mayo Clinic, Phoenix, AZ, 3Mayo Clinic Rochester, Rochester, MN, 4Mayo Clinic, Jacksonville, FL Purpose/Objective(s): Radium-223 (R223) has been shown to improve survival of patients with castration-resistant metastatic prostate cancer. The purpose of our study is to identify factors that predict the overall survival after R223 treatment (tmt). Materials/Methods: The medical records of 64 patients at our institution were reviewed. Data on patient and disease characteristics, and tmt response were collected. Kaplan-Meier estimate of survival time was calculated. Univariate analysis with log-rank method and multivariate
analysis with Cox Proportional Hazards Model were performed to evaluate factors associated with survival. Results: The results are presented in Table 1. Conclusion: In our study, several factors were associated with better survival on univariate analysis, including no prior chemotherapy, 5 bone metastases, baseline PSA36ng/ml, baseline ALP115U/L, baseline hemoglobin>12g/dl, ALP response, PSA decrease during treatment, and PSA increase less than 25% from baseline during treatment. In multivariate analysis, 5 bone metastasis, baseline ALP115U/L, and ALP response remained significant predictors of survival Author Disclosure: E. Anderson: None. W.W. Wong: None. H. Mohammadi: None. T.B. Daniels: None. S. Vora: None. S.E. Schild: None. S.R. Keole: Stock; ViewRay. C. Choo: None. K.S. Tzou: None. A. Bryce: Research Grant; Isis Pharmaceuticals, Bayer, Merck, Aragon, Novartis, BMS. T.H. Ho: None. F.J. Quevedo: None.
2621 Ten-Year Data Update: Is There Still a Role for Postoperative Radiation Therapy in High-Risk Stage III Renal Cell Carcinoma? A Retrospective Study L. Avile´s,1 M. Filomia,2 W.A. Baquero,1 L.E. Rafailovici,3 C.A. Cardiello,4 E. Fernandez,5 J. Chiozza,3 and C. Donoso6; 1Vidt Centro Medico, Buenos Aires, Argentina, 2Vidt Centro Medico - 21st. Century Oncology, Buenos Aires, Argentina, 3Vidt Centro Medico - 21st Century Oncology, Buenos Aires, Argentina, 4Hospital Militar Central, Buenos Aires 1428, Argentina, 521st Century Oncology, Fort Lauderdale, FL, 6Vidt Medical Center, Buenos Aires, Argentina Purpose/Objective(s): We updated our data with 10 year follow up to determine if there is still a role for adjuvant radiation therapy in patients of renal cell carcinoma (RCC) with adverse pathological prognostic factors, such as perirenal fat extension, capsule infiltration, positive nodes or
Abstract 2620; Table 1. Factor Baseline ECOG PS Prior chemotherapy Prior sipuleucel-T Concurrent use of zoledronate or denosumab with R223 tmt Extent of bone metastasis PSA before R223 tmt Alkaline phosphatase (ALP) before R223 tmt Hemoglobin before R223 tmt ALP response after R223 tmt PSA decrease during R223 tmt PSA increase>25% from baseline during R223 tmt
0,1 2,3 Yes No Yes No Yes No 5 lesions > 5 lesions 36ng/ml >36ng/ml 115U/L >115U/L 12g/dl >12g/dl Yes No Yes No Yes No
Median survival(mo)
12-mo survival
Univariate analysis (P value)
12.9 11.3 12.6 Not reached 16 12.8 12.8 12.9 Not reached 12.6 Not reached 11.5 Not reached 9.2 10 16 Not reached 12.5 Not reached 12.8 12.6 Not reached
67% 43% 53% 71% 76% 60% 63% 57% 100% 56% 77% 43% 87% 30% 40% 78% 80% 52% 91% 60% 56% 100%
0.62 0.028
Multivariate analysis (P value)
0.17
0.47 0.62 0.0023 <0.0001
0.0096 0.93
0.0004
0.0076
0.0026
0.75
0.015
0.02
0.0095
0.49
0.0061
0.24